iTeos Therapeutics (ITOS)
(Delayed Data from NSDQ)
$16.16 USD
-0.05 (-0.31%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $16.15 -0.01 (-0.06%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Balance Sheet
Fiscal Year End for iTeos Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 532 | 613 | 849 | 336 | 20 |
Receivables | 7 | 2 | 12 | 0 | 5 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 12 | 13 | 14 | 3 | 1 |
Total Current Assets | 551 | 628 | 875 | 340 | 26 |
Net Property & Equipment | 5 | 2 | 2 | 1 | 1 |
Investments & Advances | 101 | 118 | 0 | 0 | 0 |
Other Non-Current Assets | 5 | 1 | 2 | 3 | 3 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 1 | 1 | 1 | 0 | 0 |
Total Assets | 668 | 755 | 885 | 345 | 31 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 11 | 8 | 5 | 3 | 1 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 16 | 20 | 17 | 7 | 4 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 12 | 14 | 281 | 4 | 8 |
Total Current Liabilities | 40 | 42 | 304 | 15 | 13 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 48 | 46 | 23 | 6 | 54 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 92 | 92 | 332 | 21 | 67 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 464 | 436 | 413 | 396 | 0 |
Retained Earnings | 125 | 237 | 141 | -74 | -36 |
Other Equity | -13 | -10 | -1 | 1 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 575 | 663 | 553 | 323 | -36 |
Total Liabilities & Shareholder's Equity | 668 | 755 | 885 | 345 | 31 |
Total Common Equity | 575 | 663 | 553 | 323 | -36 |
Shares Outstanding | 35.70 | 35.50 | 35.20 | 35.00 | NA |
Book Value Per Share | 16.11 | 18.69 | 15.71 | 9.23 | 0.00 |
Fiscal Year End for iTeos Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 449 | 532 | 599 | 599 |
Receivables | NA | 6 | 7 | 6 | 4 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | NA | 25 | 12 | 14 | 12 |
Total Current Assets | NA | 480 | 551 | 619 | 615 |
Net Property & Equipment | NA | 5 | 5 | 3 | 3 |
Investments & Advances | NA | 133 | 101 | 46 | 78 |
Other Non-Current Assets | NA | 5 | 5 | 2 | 2 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 0 | 0 | 0 | 0 |
Deposits & Other Assets | NA | 1 | 1 | 1 | 1 |
Total Assets | NA | 630 | 668 | 678 | 704 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 6 | 11 | 3 | 5 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 22 | 16 | 22 | 21 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 7 | 12 | 2 | 3 |
Total Current Liabilities | NA | 36 | 40 | 28 | 30 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 48 | 46 | 46 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 89 | 92 | 79 | 80 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 471 | 464 | 456 | 449 |
Retained Earnings | NA | 86 | 125 | 155 | 187 |
Other Equity | NA | -16 | -13 | -13 | -13 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 541 | 575 | 598 | 624 |
Total Liabilities & Shareholder's Equity | NA | 630 | 668 | 678 | 704 |
Total Common Equity | 0 | 541 | 575 | 598 | 624 |
Shares Outstanding | 36.10 | 35.90 | 35.70 | 35.70 | 35.70 |
Book Value Per Share | 0.00 | 15.08 | 16.11 | 16.76 | 17.47 |